Slingshot members are tracking this event:

Aimmune Therapeutics (AIMT) Provides Update on Ongoing AR101 Phase 3 Program for Peanut Allergy Based on FDA Feedback

Do you think this event is important to the companies below? How will it affect their stock price?

Related Companies
High Medium Low
Impact on Stocks
AIMT Community voting in process

Additional Information

Additional Relevant Details The primary efficacy analysis in the ongoing Phase 3 PALISADE trial will now be conducted on ages 4-17 years, which aligns with the Breakthrough Therapy Designation population, based on the company’s discussions with the FDA. The company expects to conduct separate analyses for older patients in PALISADE. Additionally, based on FDA feedback, the company anticipates that the safety database for a potential Biologics License Application (BLA) will include data from at least 600 patients treated with AR101.
Slingshot Insights Explained
Catalyst Date
Occurred on:
Feb 16, 2017
Related Projects Image
  • Don’t see a project related to the catalyst you care about?

Related Keywords Ar101, Phase 3 Program, Peanut Allergy